The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials…
More than a third of Medicare Advantage and Part D plan enrollees are unaware that significant plan changes are expected…
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /…
KINGSTON, N.Y., Sept. 30, 2025 /PRNewswire/ -- Artemis Capital Partners ("Artemis"), a Boston-based private equity firm focused exclusively on partnering…
In this free webinar, gain insight into applying FDA and EMA safety and toxicity grading guidance to keep eCOA data…
AUSTIN, Texas, Sept. 30, 2025 /PRNewswire/ -- Oracle has been recognized as a leader in the 2025 IDC MarketScape: Worldwide Life…
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections…
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections…
Clinical operations, regulatory affairs, technical expertise, and corporate leadership additions support advancing gene therapy pipeline for cardiovascular diseasesBOSTON, Sept. 30,…
CAMPBELL, Calif., Sept. 29, 2025 /PRNewswire/ -- Saama, an established leader in AI-driven solutions and services within Health Sciences, is introducing…